Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CBX7 | O95931 | 2/20 | 0.43 |
| ▸ | CDYL2 | Q8N8U2 | 2/20 | 0.43 |
| ▸ | CDYL | Q9Y232 | 2/20 | 0.43 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13005055 | 0.94 | KDM4E (0.60) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3768011 | 0.94 | KDM4E (0.60) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13005068 | 0.93 | KDM4E (0.58) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13005057 | 0.91 | KDM4E (0.56) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13005074 | 0.91 | KDM4E (0.56) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13004994 | 0.87 | HRH3 (0.51) | KDM4EALDH1A1GAAKMT2ARECQL | |
| SCHEMBL13004990 | 0.87 | HRH3 (0.51) | KDM4EALDH1A1GAAKMT2ARECQL | |
| SCHEMBL3774050 | 0.85 | KDM4E (0.73) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL3780589 | 0.84 | KDM4E (0.63) | KDM4EALDH1A1GAAMEN1KMT2A | |
| SCHEMBL13005001 | 0.84 | HRH3 (0.48) | KDM4EALDH1A1GAARECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | KDM4E 534/4885ALDH1A1 1210/4885GAA 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.